HIV Prevention - Search News

HIV, Gilead and lenacapavir

Gilead encouraged by data on once-yearly lenacapavir for HIV prevention

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

Medical Xpress on MSN · 2d

Reformulation of HIV prevention drug lenacapavir makes it last for a year

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,

Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

The Business Journals · 3d

Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Joplin Globe · 3d

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).

MIT Technology Review22h

The Download: HIV prevention shots, and fixing a broken sex doll

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Health and Me on MSN2h

Yearly Jab For HIV Protection Is Now Almost Here

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

LGBTQ Nation on MSN1d

Once-a-year shot for HIV protection passes early safety trial

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

MIT Technology Review1d

This annual shot might protect against HIV infections

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

BlackDoctor.org16h

HIV Rates Are Dropping—But Not for Everyone. Here’s Why.

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

HIV self-testing is easy, effective — and underutilized

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

The Washington Informer2d

Empowering Women and Girls: Advancing HIV Prevention

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

2don MSN

Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

1don MSN

Hope for HIV prevention: Annual injection completes important safety trial

A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results